HIMS vs. NBIX

Last updated Apr 2, 2026

Compare and contrast key facts about Hims & Hers Health, Inc. (HIMS) and Neurocrine Biosciences, Inc. (NBIX).

Performance

HIMS vs. NBIX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Hims & Hers Health, Inc. (HIMS) and Neurocrine Biosciences, Inc. (NBIX). The values are adjusted to include any dividend payments, if applicable.

HIMS vs. NBIX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
HIMS Hims & Hers Health, Inc.	-38.90%	34.28%	171.69%	38.85%	-2.14%	-55.14%	47.47%	1.02%
NBIX Neurocrine Biosciences, Inc.	-6.54%	3.90%	3.60%	10.31%	40.24%	-11.14%	-10.83%	11.49%

Fundamentals

Market Cap HIMS : $4.92B NBIX : $13.59B
EPS HIMS : $0.51 NBIX : $4.69
PE Ratio HIMS : 38.82 NBIX : 28.25
PS Ratio HIMS : 2.12 NBIX : 4.73
PB Ratio HIMS : 9.10 NBIX : 4.18
Total Revenue (TTM) HIMS : $2.35B NBIX : $2.86B
Gross Profit (TTM) HIMS : $1.73B NBIX : $2.81B
EBITDA (TTM) HIMS : $142.44M NBIX : $719.10M

Returns By Period

In the year-to-date period, HIMS achieves a -38.90% return, which is significantly lower than NBIX's -6.54% return.

HIMS

• 1D: -4.43%
• 1M: 20.39%
• YTD: -38.90%
• 6M: -64.77%
• 1Y: -36.10%
• 3Y*: 25.99%
• 5Y*: 7.85%
• 10Y*: —

NBIX

• 1D: 0.62%
• 1M: 0.14%
• YTD: -6.54%
• 6M: -3.24%
• 1Y: 23.89%
• 3Y*: 9.41%
• 5Y*: 6.19%
• 10Y*: 12.30%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

HIMS vs. NBIX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

HIMS

HIMS Risk / Return Rank: 28
HIMS Sharpe Ratio Rank: 24
HIMS Sortino Ratio Rank: 31
HIMS Omega Ratio Rank: 31
HIMS Calmar Ratio Rank: 27
HIMS Martin Ratio Rank: 27

NBIX

NBIX Risk / Return Rank: 61
NBIX Sharpe Ratio Rank: 66
NBIX Sortino Ratio Rank: 58
NBIX Omega Ratio Rank: 60
NBIX Calmar Ratio Rank: 61
NBIX Martin Ratio Rank: 62

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

HIMS vs. NBIX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Hims & Hers Health, Inc. (HIMS) and Neurocrine Biosciences, Inc. (NBIX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	HIMS	NBIX	Difference
Sharpe ratio Return per unit of total volatility	-0.36	0.71	-1.07
Sortino ratio Return per unit of downside risk	0.10	1.13	-1.04
Omega ratio Gain probability vs. loss probability	1.01	1.16	-0.15
Calmar ratio Return relative to maximum drawdown	-0.42	0.95	-1.37
Martin ratio Return relative to average drawdown	-0.82	2.31	-3.14
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

HIMS vs. NBIX - Sharpe Ratio Comparison

The current HIMS Sharpe Ratio is -0.36, which is lower than the NBIX Sharpe Ratio of 0.71. The chart below compares the historical Sharpe Ratios of HIMS and NBIX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	HIMS	NBIX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.36	0.71	-1.07
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.09	0.19	-0.10
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.31	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.15	0.13	+0.02

Correlation

The correlation between HIMS and NBIX is 0.19, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

HIMS vs. NBIX - Dividend Comparison

Neither HIMS nor NBIX has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

HIMS vs. NBIX - Drawdown Comparison

The maximum HIMS drawdown since its inception was -87.29%, smaller than the maximum NBIX drawdown of -97.21%. Use the drawdown chart below to compare losses from any high point for HIMS and NBIX.

Drawdown Indicators

	HIMS	NBIX	Difference
Max Drawdown Largest peak-to-trough decline	-87.29%	-97.21%	+9.92%
Max Drawdown (1Y) Largest decline over 1 year	-78.06%	-20.90%	-57.16%
Max Drawdown (5Y) Largest decline over 5 years	-79.74%	-42.89%	-36.85%
Max Drawdown (10Y) Largest decline over 10 years	—	-46.39%	—
Current Drawdown Current decline from peak	-71.14%	-14.82%	-56.32%
Average Drawdown Average peak-to-trough decline	-42.66%	-44.05%	+1.39%
Ulcer Index Depth and duration of drawdowns from previous peaks	39.88%	8.59%	+31.29%

Volatility

HIMS vs. NBIX - Volatility Comparison

Hims & Hers Health, Inc. (HIMS) has a higher volatility of 43.09% compared to Neurocrine Biosciences, Inc. (NBIX) at 6.97%. This indicates that HIMS's price experiences larger fluctuations and is considered to be riskier than NBIX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	HIMS	NBIX	Difference
Volatility (1M) Calculated over the trailing 1-month period	43.09%	6.97%	+36.12%
Volatility (6M) Calculated over the trailing 6-month period	64.93%	23.03%	+41.90%
Volatility (1Y) Calculated over the trailing 1-year period	101.88%	33.89%	+67.99%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	83.69%	32.22%	+51.47%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	76.87%	39.43%	+37.44%

Financials

HIMS vs. NBIX - Profitability Comparison

The chart below illustrates the profitability comparison between Hims & Hers Health, Inc. and Neurocrine Biosciences, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

HIMS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Hims & Hers Health, Inc. reported a gross profit of 444.44M and revenue of 617.82M. Therefore, the gross margin over that period was 71.9%.

NBIX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Neurocrine Biosciences, Inc. reported a gross profit of 787.90M and revenue of 805.50M. Therefore, the gross margin over that period was 97.8%.

HIMS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Hims & Hers Health, Inc. reported an operating income of 9.19M and revenue of 617.82M, resulting in an operating margin of 1.5%.

NBIX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Neurocrine Biosciences, Inc. reported an operating income of 210.90M and revenue of 805.50M, resulting in an operating margin of 26.2%.

HIMS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Hims & Hers Health, Inc. reported a net income of 20.60M and revenue of 617.82M, resulting in a net margin of 3.3%.

NBIX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Neurocrine Biosciences, Inc. reported a net income of 153.70M and revenue of 805.50M, resulting in a net margin of 19.1%.